Trial Profile
A randomized, placebo controlled, double-blind, double-dummy, 3-period cross-over study in adult patients with autism spectrum disorders evaluating cognitive response, eye-gaze, and heart rate variability after single-dose oxytocin 8 or 24 IU intranasal administration using the OptiNose bi-directional nose-to-brain device.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2020
Price :
$35
*
At a glance
- Drugs Oxytocin (Primary)
- Indications Autistic disorder; Pervasive child development disorders
- Focus Therapeutic Use
- Sponsors OptiNose; OptiNose AS
- 06 Nov 2020 Status changed from recruiting to completed.
- 06 Oct 2015 Status changed from planning to recruiting, as per Optinose media release.
- 21 Jul 2015 New trial record